IOVANCE BIOTHERAPEUT

IOVA
Delayed Quote. Delayed  - 07/23 04:00:00 pm
23.05USD -0.95%
Valuation
Fiscal Period: December 2020 2021
Capitalization1 6 8063 523
Entreprise Value (EV)1 6 1773 118
P/E ratio -24,7x-11,2x
Yield --
Capitalization / Revenue --
EV / Revenue --
EV / EBITDA -23,7x-9,80x
Price to Book --
Nbr of stocks (in thousands) 146 687152 849
Reference price (USD) 46,423,1
Announcement Date 02/25/2021-
Previous period Next period
1 USD in Million
Estimates
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: December 2020 2021
Net sales1 --
EBITDA1 -261-318
Operating profit (EBIT)1 -262-308
Operating Margin --
Pre-Tax Profit (EBT)1 -260-306
Net income1 -260-306
Net margin --
EPS2 -1,88-2,06
Dividend per Share --
Announcement Date 02/25/2021-
Previous period Next period
1 USD in Million
2 USD
Finances - Leverage
Fiscal Period: December 2020 2021
Net Debt1 --
Net Cash position1 629405
Leverage (Debt / EBITDA) 2,41x1,27x
Free Cash Flow1 -252-250
ROE (Net Profit / Equities) --
Shareholders' equity1 --
ROA (Net Profit / Asset) --
Assets1 --
Book Value Per Share --
Cash Flow per Share --
Capex1 46,837,7
Capex / Sales --
Announcement Date 02/25/2021-
Previous period Next period
1 USD in Million
Financial Ratios
Size 2021e 2022e
Capitalization 3 523 M $ -
Entreprise Value (EV) 3 118 M $ 3 371 M $
Valuation 2021e 2022e
P/E ratio (Price / EPS) -11,2x -10,5x
Capitalization / Revenue - 906x
EV / Revenue - 802x
EV / EBITDA -9,80x -8,83x
Yield (DPS / Price) - -
Price to book (Price / BVPS) - -
Profitability 2021e 2022e
Operating Margin (EBIT / Sales) - -8 692%
Operating Leverage (Delta EBIT / Delta Sales) - -
Net Margin (Net Profit / Revenue) - -8 633%
ROA (Net Profit / Asset) - -
ROE (Net Profit / Equities) - -
Rate of Dividend - -
Balance Sheet Analysis 2021e 2022e
CAPEX / Sales   - 463%
Cash Flow / Sales - -
Capital Intensity (Assets / Sales) - -
Financial Leverage (Net Debt / EBITDA) - -
EPS & Dividend